• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

NICE shuns Novo Nordisk's obesity med Saxenda, citing CV questions

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 26, 2020 at 01:42: PM
via Novo Nordisk bet big on its GLP-1 med Saxenda in obesity, despite rivals' failures to expand the global market. But payers in England have put up a roadblock that could hurt the Danish drugmaker's sales efforts. NICE rejected Saxenda for use on England's NHS, citing its list price and lack of long-term efficacy data in draft guidance published Friday.

article source
 




Top Bottom
Back
Quote